NeuroRx, Relief Therapeutics secure FDA fast track status for Covid-19 drug candidate

This article was originally published here

RLF-100 is a synthetic form of human vasoactive intestinal peptide (VIP), which minimises inflammation in the lungs and protects the alveolar type II cells that are considered to

The post NeuroRx, Relief Therapeutics secure FDA fast track status for Covid-19 drug candidate appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply